241 related articles for article (PubMed ID: 1788749)
1. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].
Weiss T; Griesshaber J; Rogatti W; Kistner O; Hsu E; Jansen T; Diehm C
Vasa Suppl; 1991; 33():341-2. PubMed ID: 1788749
[TBL] [Abstract][Full Text] [Related]
2. [Placebo controlled study of the effect of intravenous PGE1 on macro- and microcirculation in patients with stage III/IV arterial occlusive disease].
Scheffler P; de la Hamette D; Leipnitz G
Vasa Suppl; 1991; 33():343-4. PubMed ID: 1788750
[TBL] [Abstract][Full Text] [Related]
3. Skin oxygen pressure histograms in patients with peripheral arterial occlusive disease during intraarterial and intravenous prostaglandin E1 infusions of different dosages and their prognostic value.
Creutzig A; Arnold A; Caspary L; Thum J; Alexander K
Angiology; 1995 May; 46(5):357-67. PubMed ID: 7741319
[TBL] [Abstract][Full Text] [Related]
4. Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease.
Thum J; Caspary L; Creutzig A; Alexander K
Vasa; 1998 May; 27(2):100-5. PubMed ID: 9612114
[TBL] [Abstract][Full Text] [Related]
5. Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross-over study in patients with critical limb ischemia.
Schellong S; Altmann E; von Bilderling P; Rudofsky G; Waldhausen P; Rogatti W
Prostaglandins Leukot Essent Fatty Acids; 2004 Jun; 70(6):503-9. PubMed ID: 15120713
[TBL] [Abstract][Full Text] [Related]
6. [Intra-arterial infusion of PGE1 alpha cyclodextrin].
Laurora G; Cesarone MR; Belcaro G; Incandela L; De Sanctis MT; Fascetti E; D'Archivio C
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):17-20. PubMed ID: 10658440
[TBL] [Abstract][Full Text] [Related]
7. A comparative analysis of transcutaneous oximetry (tcPO2) during oxygen inhalation and leg dependency in severe peripheral arterial occlusive disease.
Scheffler A; Rieger H
J Vasc Surg; 1992 Aug; 16(2):218-24. PubMed ID: 1495145
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.
Balzer K; Rogatti W; Rüttgerodt K
Vasa Suppl; 1989; 28():31-8. PubMed ID: 2609242
[TBL] [Abstract][Full Text] [Related]
9. Transcutaneous oxygen pressure as predictive parameter for ulcer healing in endstage vascular patients treated with spinal cord stimulation.
Claeys LG; Horsch S
Int Angiol; 1996 Dec; 15(4):344-9. PubMed ID: 9127776
[TBL] [Abstract][Full Text] [Related]
10. [Intravenous and intra-arterial prostaglandin E1 treatment in patients with stage IIb arterial occlusive disease].
Rudofsky G
Vasa Suppl; 1988; 23():121-5. PubMed ID: 3206330
[No Abstract] [Full Text] [Related]
11. Transcutaneous oxygen tension (TcPO2) in the testing period of spinal cord stimulation (SCS) in critical limb ischemia of the lower extremities.
Petrakis IE; Sciacca V
Int Surg; 1999; 84(2):122-8. PubMed ID: 10408282
[TBL] [Abstract][Full Text] [Related]
12. [Vital capillary microscopic examination and transcutaneous pO2-measurements by intravenous prostaglandin E1 infusion].
Heidrich H; Lammersen T
Dtsch Med Wochenschr; 1985 Aug; 110(34):1283-5. PubMed ID: 4040847
[TBL] [Abstract][Full Text] [Related]
13. [Double-blind placebo-controlled study of the behavior of tcPO2 during intravenous infusion of prostaglandin E1 in patients with severe arterial occlusive disease].
Creutzig A; Caspary L; Alexander K
Vasa Suppl; 1992; 35():36-8. PubMed ID: 1481055
[No Abstract] [Full Text] [Related]
14. [Transcutaneous and intracutaneous pO2 measurements in the assessment of peripheral arterial occlusive diseases].
Reuter U; Setlak P; Petrow C; Altmann E; Sinz V
Z Gesamte Inn Med; 1987 Apr; 42(7):178-82. PubMed ID: 3604349
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of intravenously applied prostaglandin E1.
Scheffler P; de la Hamette D; Leipnitz G
Vasa Suppl; 1989; 28():19-25. PubMed ID: 2609240
[TBL] [Abstract][Full Text] [Related]
16. [Intravenous administration of PGE1: studies of the effectiveness and duration of the effect of various dosages based on flow measurements of the femoral artery in patients with healthy vessels and in stage IIb arterial occlusive disease].
Scheffler P; Birkel L; Grub KR; de la Hamette D
Vasa Suppl; 1988; 23():126-9. PubMed ID: 3061035
[No Abstract] [Full Text] [Related]
17. [Long-term blood pressure measurements with i.v. prostaglandin E1 infusion].
Heidrich H; Brodel C; Meuche C; Hellmann G; Ranft J
Vasa Suppl; 1989; 27():46. PubMed ID: 2623542
[No Abstract] [Full Text] [Related]
18. [Transcutaneous oxygen partial pressure and systolic malleolar artery pressure in patients with peripheral arterial occlusive disease. Longitudinal measurements over 14 days].
Heidrich H; Lammersen T
Med Klin (Munich); 1993 Oct; 88(10):564-7. PubMed ID: 8272016
[TBL] [Abstract][Full Text] [Related]
19. [O2 inhalation and lowering leg position as a provocation test for transcutaneous measurement of partial oxygen pressure (tcpO2) in advanced peripheral arterial occlusive disease].
Scheffler A; Rieger H
Vasa Suppl; 1991; 33():269-70. PubMed ID: 1788709
[No Abstract] [Full Text] [Related]
20. Clinical information content of transcutaneous oxymetry (tcpO2) in peripheral arterial occlusive disease (a review of the methodological and clinical literature with a special reference to critical limb ischaemia).
Scheffler A; Rieger H
Vasa; 1992; 21(2):111-26. PubMed ID: 1621428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
